The 2021 HPTN Annual Meeting took place virtually May 17, 19, and 21. The meeting featured a variety of HIV and COVID-19 prevention research presentations and discussions, as well as interactive Q&A sessions.
May 17, 2021
Title | Speaker |
SURVIVING SARS-COV2: LESSONS FROM 40+ YEARS OF HIV RESEARCH | Dr. Myron S. Cohen |
HPTN: SCIENTIFIC AIMS FOR 2021 AND BEYOND | Dr. Wafaa M. El-Sadr |
MULTIPURPOSE PREVENTION TECHNOLOGIES FOR HIV PREVENTION: THE VISION, THE APPROACHES, AND THE CHALLENGES | Dr. Julie Pulerwitz and Dr. Lisa Haddad |
CABOTEGRAVIR ROUNDTABLE DISCUSSION: PAST, PRESENT AND FUTURE |
Dr. Raphael J. Landovitz (HPTN 083) Dr. Sinead Delany-Moretlwe (HPTN 084) Dr. Sybil Hosek (HPTN 083-01/HPTN 084-01) |
HPTN 083: HIV VIROLOGY AND DRUG RESISTANCE IN THE SETTING OF CAB LA PREP | Dr. Susan Eshleman |
HIV PREVENTION AND THE VAGINAL MICROBIOME | Dr. Betsy Herold |
SOURCE AND RECIPIENT CHARACTERISTICS OF HIV TRANSMISSION PAIRS IDENTIFIED IN THE HPTN 071 PHYLOGENETICS PROJECT | Dr. Matthew Hall |
May 19, 2021
May 21, 2021
Title | Speaker |
HPTN 091: LESSONS LEARNED INCORPORATING LIVED EXPERIENCES TO STRENGTHEN RESEARCH DESIGN | Nora Howell |
USING CROSS-SECTIONAL RECENCY ASSAYS TO ASSESS PREVENTION EFFICACY: FUTURE TRIAL DESIGN AND SAMPLE SIZE CONSIDERATIONS | Dr. Fei Gao |
WHAT IS A WIN? DEFINING EFFICACY GOALS IN A TRIAL DESIGNED WITH A PLACEBO COUNTERFACTUAL | Dr. Jim Hughes |
ESTIMATING THE EFFICACY OF LONG-ACTING PREP WITH A MODEL-BASED COUNTERFACTUAL PLACEBO | Dr. Mia Moore |
ESTIMATING THE IMPACT OF PREP REGIMENS CONTAINING LONG-ACTING INJECTABLE CABOTEGRAVIR OR DAILY ORAL TDF/FTC AMONG MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES: MATHEMATICAL MODELLING FOR HPTN 083 | Dr. Kate Mitchell |
NETWORK AWARDS | Dr. Quarraisha Abdool Karim |